Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Smooth Drug Development Selects CRO Starter Kit™ CTMS by Flex Databases

Published: Monday, September 23, 2013
Last Updated: Monday, September 23, 2013
Bookmark and Share
Flex Databases to release an electronic data capture (EDC) product in Q4 2013.

Flex Databases has announced that Smooth Drug Development has selected Flex CRO Starter Kit™ as its CTMS solution.

Smooth Drug Development is a full-service CRO headquartered in St. Petersburg, Russia. Smooth performs phase I-IV studies and runs 2 phase I units in St. Petersburg.

"We looked at a number of solutions on the market", said Dmitry Morozovsky, CEO of Smooth Drug Development. "In Flex Databases we found a solution which gives us the breadth of functionality we have not seen before, as Flex provide both PSA (such as timesheets, budgets, planning, utilization) and clinical research tools on the same platform. What especially caught our attention is the fact that Flex Databases are going to be releasing an electronic data capture (EDC) product in Q4 2013. We run a lot of bioequivalence studies, where operational efficiency is crucial, and having a single platform bringing together resource management, CTMS and EDC will allow us to shorten study timelines and further improve performance on the studies we run."

"Smooth Drug Development are a forward looking dynamic company who were quick to see the value of our platform", said Timur Galimov, Technical Director at Flex Databases.

Galimov continued, "We come across a lot of interest towards our upcoming EDC product, and we are pleased to have found an early adopter of our EDC technology even before the product has been released. Smooth Drug Development have one of the most comprehensive offerings we have seen in clinical research, and we are keen to help them grow by offering a platform which will streamline all the processes of their business".


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Flex Databases Launches New Web Site
New website cements the company's unique positioning as a PSA company.
Tuesday, March 25, 2014
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!